SBIR/STTR Research Award

LOW RANGE NUCLEIC ACID CONTROLS FOR M. TUBERCULOSIS

Award identifier b49357b94aa8359b80480d66bcf7883c4772fcaa091fc147c29122be32a25461Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$120,229

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
MAINE MOLECULAR QUALITY CONTROLS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Low Range Nucleic Acid Controls for M. tuberculosis -- The goal of this Small Business Innovation Research Grants (SBIR) Phase I application is to demonstrate feasibility of producing quantitative, synthetic, non-infectious quality controls for molecular Mtb testing. Laboratories will use these products to monitor the lower detection range of Mtb deoxyribonucleic acid (DNA) tests, thus ensuring the accuracy of patient results. Two novel approaches will be used. The Mtb DNA will be bound in defined quantity to microparticulate surfaces through innovative oligonucleotide hybrid links. The hybrid is designed to melt and quantitatively release nucleic acid when subjected to a Mtb DNA extraction protocol. In another approach, Mtb DNA will be cloned in low copy number in laboratory bacteria. Innovative techniques will be developed to cross link the bacterial membrane to produce lysis resistance comparable to the Mtb. Both products will be tested in all steps of a commercial assay. Technology developed in this project will be used to produce and commercialize a family of quantitative molecular controls for the diagnostics industry. Stable, non-infectious quality control materials for molecular assays are not widely available; limiting the widespread adoption of these tests. Molecular testing for tuberculosis (TB) or other diseases is an important medical advance; therefore public health will directly benefit from products supporting this testing.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.